Loading…
Loading…
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
[url="]Zai Lab Limited[/url] (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company's internally dev
PHILADELPHIA, Oct. 9, 2026 /PRNewswire/ -- Kaskela Law announces that it is investigating Array Digital Infrastructure, Inc. (NYSE: AD) ("Array Digital") on behalf of the company's shareholders. Register here for additional information: https://kaskelalaw.com/case/array-digital/ Year to date, shares of Array Digital's common stock have generated an investment return of negative 38% , as compared to the S&P 500's investment return of approximately 13% over that same time period.
Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple I
Array Digital Infrastructure Inc. (NYSE: AD - Get Free Report) hit a new 52-week low during mid-day trading on Monday. The company traded as low as $33.70 and last traded at $33.6640, with a volume of 37207 shares. The stock had previously closed at $34.49. Wall Street Analyst Weigh In A number of research firms have
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026PR
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw